DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and kidney diseases using its lead drug candidate DM199, a human tissue kallikrein-1 protein. The drug is currently in Phase 2 REDUX and Phase 2/3 REMEDY2 trials for treating patients with chronic kidney disease caused by diabetes and acute ischemic stroke respectively. The company is also working on a preclinical stage drug, DM300, for treating inflammatory diseases.